Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus

Journal of the American Society of Nephrology

Volumn 15, Issue 12, 2004, Pages 3166-3174

  Abbott, Kevin C ^a,b   Lentine, Krista L ^c   Bucci, Jay R ^a,b   Agodoa, Lawrence Y ^d   Koff, Jonathan M ^a,b   Holtzmuller, Kent C ^a,b   Schnitzler, Mark A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; HEPATITIS C ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION DIABETES; POSTTRANSPLANTATION HEPATITIS C; PRIORITY JOURNAL; SURVIVAL;

EID: 9644303150     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000145439.48387.BF     Document Type: Article

References (37)

1. Abbott KC, Bucci JR, Matsumoto CS, SJ, Agodoa LY, Holtzmuller KC, Cruess DF, Peters TG: Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 14: 2908-2918, 2003
2. Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Peters TG, Abbott KC: Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 13: 2974-2982, 2002
3. Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC: Hepatitis C virus seropositivity at the time of renal transplantation in the United States: Associated factors and patient survival. Am J Transplant 1: 179-184, 2001
4. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S: Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65: 667-670, 1998
5. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S: Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 66: 471-476, 1998
6. Pereira BJ, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325: 454-460, 1991
7. Roth D, Fernandez JA, Babischkin S, De Mattos A, Buck BE, Quan S, Olson L, Burke GW, Nery JR, Esquenazi V: Detection of hepatitis C virus infection among cadaver organ donors: Evidence for low transmission of disease. Ann Intern Med 117: 470-475, 1992
8. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC, Bailey TC: The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation. Am J Kidney Dis 29: 428-434, 1997
9. Schnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC: The association of cytomegalovirus seropairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant 3: 445-451, 2003
10. Abbott KC, Hypolite IO, Viola R, Poropatich RK, Hshieh P, Cruess D, Hawkes CA, Agodoa LY: Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 12: 402-409, 2002
11. Schnitzler MA, Woodward RS, Brennan DCPhelan DL, Spitznagel EL, Boxerman SB, Dunagan WC, Bailey TC: Cytomegalovirus and HLA-A, B, and DR locus interactions: Impact on renal transplant graft survival. Am J Kidney Dis 30: 766-771, 1997
12. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13: 1374-1380, 2002
13. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, Woodworth TG, Brennan DC: Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3: 590-598, 2003
14. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178-185, 2003
15. Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY: Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 14: 2358-2365, 2003
16. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 11: 520-529, 2000
17. Schnitzler MA, Whiting JF, Brennan DC, Lin G, Chapman W, Lowell J, Boxerman S, Hardinger KL, Kalo Z: The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation 75: 1940-1945, 2003
18. Matas AJ, Schnitzler M: Payment for living donor (vendor) kidneys: A cost-effectiveness analysis. Am J Transplant 4: 216-221, 2004
19. Whiting JF, Kiberd B, Kalo Z, Keown P, Roels L, Kjerulf M: Cost-effectiveness of organ donation: Evaluating investment into donor action and other donor initiatives. Am J Transplant 4: 569-573, 2004
20. Roels L, Kalo Z, Boesebeck D, Whiting J, Wight C: Cost-benefit approach in evaluating investment into donor action: The German case. Transpl Int 16: 321-326, 2003
21. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K: Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848, 2004
22. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA: New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 10: 349-355, 2004
23. Gursoy M, Guvener N, Koksal R, Karavelioglu D, Baysal C, Ozdemir N, Boyacioglu S, Bilgin N, Erdal R: Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 32: 561-562, 2000
24. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM: Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3: 357-360, 2003
25. Gane E, Pilmore H: Management of chronic viral hepatitis before and after renal transplantation. Transplantation 74: 427-437, 2002
26. Natov SN, Pereira BJ: Management of hepatitis C infection in renal transplant recipients. Am J Transplant 2: 483-490, 2002
27. Morales JM, Campistol JM, Dominguez-Gil B: Hepatitis C virus infection and kidney transplantation. Semin Nephrol 22: 365-374, 2002
28. Campistol JM, Esforzado N, Morales JM: Hepatitis C virus-positive patients on the waiting list for transplantation. Semin Nephrol 22: 361-364, 2002
29. Gonzalez-Roncero F, Gentil MA, Valdivia MA, Algarra G, Pereira P, Toro J, Sayago M, Mateos J: Outcome of kidney transplant in chronic hepatitis C virus patients: Effect of pre-transplantation interferon-α2b monotherapy. Transplant Proc 35: 1745-1747, 2003
30. Zeuzem S: Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Ann Intern Med 140: 370-381, 2004
31. Mandal AK, Kraus ES, Samaniego M, Rai R, Humphreys SL, Ratner LE, Maley WR, Burdick JF: Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 14[Suppl]:391-396, 2000
32. Petrone H, Martinoia A, Ferreiro E, Montecchia G, Belloni P, Barbero R, Pianzola H, Casaliba A, Menna ME, Nagy P: Renal transplant waiting list exclusion causes: Hepatitis C virus infection and liver disease prevalence. Transplant Proc 31: 3038-3040, 1999
33. Zucker K, Cirocco R, Roth D, Olson L, Burke GW, Nery J, Esquenazi V, Miller J: Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 57: 832-840, 1994
34. Widell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I: Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 60: 642-647, 1995
35. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14: 3270-3277, 2003
36. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367, 2001
37. Gentil MA, Lopez M, Gonzalez-Roncero F, Rodriguez-Algarra G, Pereira P, Lopez R, Martinez M, Toro J, Mateos J: Hepatitis C and the incidence of diabetes mellitus after renal transplant: Influence of new immunosuppression protocols. Transplant Proc 35: 1748-1750, 2003